Annual CFO
-$51.66 M
+$52.14 M+50.23%
December 31, 2023
Summary
- As of February 26, 2025, RLMD annual cash flow from operations is -$51.66 million, with the most recent change of +$52.14 million (+50.23%) on December 31, 2023.
- During the last 3 years, RLMD annual CFO has fallen by -$23.85 million (-85.77%).
- RLMD annual CFO is now -679626.32% below its all-time high of -$7600.00, reached on August 31, 2012.
Performance
RLMD Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$16.66 M
-$3.39 M-25.59%
September 30, 2024
Summary
- As of February 26, 2025, RLMD quarterly cash flow from operations is -$16.66 million, with the most recent change of -$3.39 million (-25.59%) on September 30, 2024.
- Over the past year, RLMD quarterly CFO has dropped by -$3.62 million (-27.77%).
- RLMD quarterly CFO is now -1110526.67% below its all-time high of $1500.00, reached on November 30, 2012.
Performance
RLMD Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$53.21 M
-$5.03 M-10.43%
September 30, 2024
Summary
- As of February 26, 2025, RLMD TTM cash flow from operations is -$53.21 million, with the most recent change of -$5.03 million (-10.43%) on September 30, 2024.
- Over the past year, RLMD TTM CFO has dropped by -$5.01 million (-10.41%).
- RLMD TTM CFO is now -3547153.33% below its all-time high of $1500.00, reached on November 30, 2012.
Performance
RLMD TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
RLMD Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +50.2% | -27.8% | -10.4% |
| 3 y3 years | -85.8% | +20.4% | +13.0% |
| 5 y5 years | -392.1% | -557.3% | -368.3% |
RLMD Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +50.2% | -62.5% | +55.8% | -10.4% | +49.6% |
| 5 y | 5-year | -705.4% | +50.2% | -557.3% | +55.8% | -452.7% | +49.6% |
| alltime | all time | <-9999.0% | +50.2% | <-9999.0% | +55.8% | <-9999.0% | +49.6% |
Relmada Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$16.66 M(+25.6%) | -$53.21 M(+10.4%) |
| Jun 2024 | - | -$13.26 M(+1.7%) | -$48.18 M(-0.0%) |
| Mar 2024 | - | -$13.04 M(+27.2%) | -$48.19 M(-6.7%) |
| Dec 2023 | -$51.66 M(-50.2%) | -$10.25 M(-11.9%) | -$51.66 M(-33.2%) |
| Sep 2023 | - | -$11.63 M(-12.4%) | -$77.29 M(-16.5%) |
| Jun 2023 | - | -$13.27 M(-19.6%) | -$92.52 M(-8.3%) |
| Mar 2023 | - | -$16.51 M(-54.0%) | -$100.88 M(-2.8%) |
| Dec 2022 | -$103.80 M(+13.0%) | -$35.88 M(+33.6%) | -$103.80 M(-1.7%) |
| Sep 2022 | - | -$26.86 M(+24.2%) | -$105.58 M(+6.0%) |
| Jun 2022 | - | -$21.63 M(+11.3%) | -$99.63 M(+4.6%) |
| Mar 2022 | - | -$19.43 M(-48.4%) | -$95.22 M(+3.6%) |
| Dec 2021 | -$91.87 M(+230.4%) | -$37.66 M(+80.1%) | -$91.87 M(+50.3%) |
| Sep 2021 | - | -$20.92 M(+21.5%) | -$61.14 M(+16.0%) |
| Jun 2021 | - | -$17.21 M(+7.0%) | -$52.73 M(+30.3%) |
| Mar 2021 | - | -$16.09 M(+132.2%) | -$40.47 M(+45.5%) |
| Dec 2020 | -$27.81 M(+333.6%) | -$6.93 M(-44.6%) | -$27.81 M(+33.2%) |
| Sep 2020 | - | -$12.50 M(+152.4%) | -$20.88 M(+91.3%) |
| Jun 2020 | - | -$4.95 M(+44.6%) | -$10.91 M(+13.4%) |
| Mar 2020 | - | -$3.42 M(+35.1%) | -$9.63 M(-15.3%) |
| Dec 2019 | -$6.41 M(-38.9%) | - | - |
| Sep 2019 | - | -$2.53 M(-30.9%) | -$11.36 M(+8.2%) |
| Jun 2019 | -$10.50 M | -$3.67 M(+82.3%) | -$10.50 M(+15.4%) |
| Mar 2019 | - | -$2.01 M(-36.1%) | -$9.10 M(+4.4%) |
| Dec 2018 | - | -$3.15 M(+88.4%) | -$8.71 M(+30.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$1.67 M(-26.3%) | -$6.69 M(+11.5%) |
| Jun 2018 | -$6.00 M(-7.2%) | -$2.27 M(+39.4%) | -$6.00 M(+26.3%) |
| Mar 2018 | - | -$1.63 M(+43.6%) | -$4.75 M(-4.6%) |
| Dec 2017 | - | -$1.13 M(+15.6%) | -$4.98 M(-6.0%) |
| Sep 2017 | - | -$979.00 K(-3.7%) | -$5.30 M(-18.0%) |
| Jun 2017 | -$6.47 M(-50.8%) | -$1.02 M(-45.2%) | -$6.47 M(-21.9%) |
| Mar 2017 | - | -$1.85 M(+27.9%) | -$8.28 M(-17.6%) |
| Dec 2016 | - | -$1.45 M(-32.4%) | -$10.05 M(-16.8%) |
| Sep 2016 | - | -$2.14 M(-24.1%) | -$12.07 M(-8.2%) |
| Jun 2016 | -$13.14 M(-19.0%) | -$2.83 M(-22.1%) | -$13.14 M(-11.2%) |
| Mar 2016 | - | -$3.63 M(+4.4%) | -$14.81 M(-5.2%) |
| Dec 2015 | - | -$3.48 M(+8.1%) | -$15.61 M(-8.8%) |
| Sep 2015 | - | -$3.22 M(-28.4%) | -$17.12 M(+5.5%) |
| Jun 2015 | -$16.23 M(+649.7%) | -$4.49 M(+1.3%) | -$16.23 M(+38.2%) |
| Mar 2015 | - | -$4.43 M(-11.1%) | -$11.74 M(+60.6%) |
| Dec 2014 | - | -$4.98 M(+114.6%) | -$7.31 M(+213.1%) |
| Sep 2014 | - | -$2.32 M(>+9900.0%) | -$2.33 M(>+9900.0%) |
| Jun 2014 | -$2.16 M(>+9900.0%) | - | - |
| Feb 2014 | - | -$3500.00(-61.5%) | -$23.00 K(+2.7%) |
| Nov 2013 | - | -$9100.00(+68.5%) | -$22.40 K(+89.8%) |
| Aug 2013 | -$11.90 K(+56.6%) | -$5400.00(+8.0%) | -$11.80 K(+84.4%) |
| May 2013 | - | -$5000.00(+72.4%) | -$6400.00(+357.1%) |
| Feb 2013 | - | -$2900.00(-293.3%) | -$1400.00(-193.3%) |
| Nov 2012 | - | $1500.00 | $1500.00 |
| Aug 2012 | -$7600.00 | - | - |
FAQ
- What is Relmada Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Relmada Therapeutics?
- What is Relmada Therapeutics annual CFO year-on-year change?
- What is Relmada Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Relmada Therapeutics?
- What is Relmada Therapeutics quarterly CFO year-on-year change?
- What is Relmada Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Relmada Therapeutics?
- What is Relmada Therapeutics TTM CFO year-on-year change?
What is Relmada Therapeutics annual cash flow from operations?
The current annual CFO of RLMD is -$51.66 M
What is the all time high annual CFO for Relmada Therapeutics?
Relmada Therapeutics all-time high annual cash flow from operations is -$7600.00
What is Relmada Therapeutics annual CFO year-on-year change?
Over the past year, RLMD annual cash flow from operations has changed by +$52.14 M (+50.23%)
What is Relmada Therapeutics quarterly cash flow from operations?
The current quarterly CFO of RLMD is -$16.66 M
What is the all time high quarterly CFO for Relmada Therapeutics?
Relmada Therapeutics all-time high quarterly cash flow from operations is $1500.00
What is Relmada Therapeutics quarterly CFO year-on-year change?
Over the past year, RLMD quarterly cash flow from operations has changed by -$3.62 M (-27.77%)
What is Relmada Therapeutics TTM cash flow from operations?
The current TTM CFO of RLMD is -$53.21 M
What is the all time high TTM CFO for Relmada Therapeutics?
Relmada Therapeutics all-time high TTM cash flow from operations is $1500.00
What is Relmada Therapeutics TTM CFO year-on-year change?
Over the past year, RLMD TTM cash flow from operations has changed by -$5.01 M (-10.41%)